INNOPRAN XL Drug Patent Profile

✉ Email this page to a colleague

Which patents cover Innopran Xl, and what generic alternatives are available?

Innopran Xl is a drug marketed by Ani Pharms and is included in one NDA.

The generic ingredient in INNOPRAN XL is propranolol hydrochloride. There are twenty-two drug master file entries for this compound. Forty-one suppliers are listed for this compound. Additional details are available on the propranolol hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Innopran Xl

A generic version of INNOPRAN XL was approved as propranolol hydrochloride by INNOGENIX on October 22^nd, 1985.

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for INNOPRAN XL?
What are the global sales for INNOPRAN XL?
What is Average Wholesale Price for INNOPRAN XL?

Summary for INNOPRAN XL

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	157
Clinical Trials:	4
Patent Applications:	3,873
Drug Prices:	Drug price information for INNOPRAN XL
What excipients (inactive ingredients) are in INNOPRAN XL?	INNOPRAN XL excipients list
DailyMed Link:	INNOPRAN XL at DailyMed

Drug patent expirations by year for INNOPRAN XL

Recent Clinical Trials for INNOPRAN XL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
United States Department of Defense	Early Phase 1
University of Missouri-Columbia	Early Phase 1
University of North Carolina, Chapel Hill	Phase 2

See all INNOPRAN XL clinical trials

Pharmacology for INNOPRAN XL

Drug Class	beta-Adrenergic Blocker
Mechanism of Action	Adrenergic beta-Antagonists

US Patents and Regulatory Information for INNOPRAN XL

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ani Pharms	INNOPRAN XL	propranolol hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	021438-001	Mar 12, 2003	BX	RX	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Ani Pharms	INNOPRAN XL	propranolol hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	021438-002	Mar 12, 2003	BX	RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for INNOPRAN XL

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Ani Pharms	INNOPRAN XL	propranolol hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	021438-001	Mar 12, 2003	⤷ Sign Up	⤷ Sign Up
Ani Pharms	INNOPRAN XL	propranolol hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	021438-002	Mar 12, 2003	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for INNOPRAN XL

See the table below for patents covering INNOPRAN XL around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
South Korea	20040084890		⤷ Sign Up
World Intellectual Property Organization (WIPO)	03028708		⤷ Sign Up
Australia	2002330211		⤷ Sign Up
European Patent Office	1432411	FORMES POSOLIGIQUES MULTIPARTICULAIRES A LIBERATION PROGRAMMEE ET PROLONGEE DE PROPANOLOL (TIMED, SUSTAINED RELEASE MULTI-PARTICULATE DOSAGE FORMS OF PROPRANOLOL)	⤷ Sign Up
Japan	4369752		⤷ Sign Up
Japan	2005508922		⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

AI Research Assistant

Questions you can ask:

Summary for INNOPRAN XL

Recent Clinical Trials for INNOPRAN XL

Pharmacology for INNOPRAN XL

Make Better Decisions: Try a trial or see plans & pricing